Frankfurt
07.07.25 | 08:06
0,023 Euro
-18,05 % -0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | Acarix AB: Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor System in U.S. Emergency Departments | 109 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®... ► Artikel lesen | |
| 16.06. | Acarix AB: Acarix Achieves First Fixed U.S. Reimbursement Milestone for CADScor at $300.00 USD | 125 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix a global leader in AI and acoustics-based cardiac diagnostics, is pleased to announce that the first payor has agreed to provide fixed reimbursement for the CADScor® System at... ► Artikel lesen | |
| 12.05. | Acarix AB: Acarix Publishes Interim Report, January - March 2025 | 170 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the first quarter of 2025. The report highlights continued growth in the U.S.... ► Artikel lesen | |
| 13.02. | Acarix Publishes Year-End Report 2024 - Sales and revenue for the CADScor System and patches are surging amid ongoing U.S. expansion efforts | 243 | PR Newswire | OKLAHOMA CITY, Feb. 13, 2025 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2024 year-end financial results. "The company continues... ► Artikel lesen | |
| ACARIX Aktie jetzt für 0€ handeln | |||||
| 07.11.24 | Acarix AB: Acarix Publishes Third Quarter 2024 Report | 152 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the third quarter of 2024. The company has made significant progress toward operational... ► Artikel lesen | |
| 22.08.24 | Acarix AB (publ) publishes Interim Report, April - June 2024 | 239 | PR Newswire | NEW YORK, Aug. 22, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved... ► Artikel lesen | |
| 15.07.24 | Acarix Shares Begin Trading on the US-based OTCQB Market | 190 | PR Newswire | NEW YORK, July 15, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 47,860 | +0,19 % | EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Fresenius Medical Care AG
Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 52,30 | -2,43 % | Carl Zeiss Meditec-Aktie: Das sieht nicht gut aus | Die Aktie von Carl Zeiss Meditec steht zum Wochenstart erneut unter Druck. Doch was sorgt jetzt für Belastung? Und gibt es Chancen bei dem Wert nach einer jahrelang schlechten Performance? Druck aus... ► Artikel lesen | |
| ECKERT & ZIEGLER | 66,70 | +0,45 % | UNGLAUBLICHE Sondermeldung bei Eckert & Ziegler Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| UNITEDHEALTH | 263,35 | +0,15 % | Schlussglocke: KI-Euphorie stockt - Old Economy dreht auf - United Health und Nike besonders ... | Zum Auftakt des zweiten Börsenhalbjahres gönnten sich S&P?500 und Nasdaq?100 eine Verschnaufpause. Der Tech-lastige Nasdaq?100 verlor 0,89 Prozent auf 22.478 Punkte, der S&P?500 sank moderat um 0,11... ► Artikel lesen | |
| HIMS & HERS HEALTH | 40,230 | +1,59 % | Dr. Dennis Riedl: Bitcoin, Hims & Hers und Paypal im Check | ||
| BICO GROUP | 3,252 | -0,18 % | Toni Haberthür, CEO Bico / Hilding Anders Switzerland, im Interview | von Patrick Gunti Moneycab.com: Herr Haberthür, Bico steht «für ä tüüfä gsundä Schlaaf» und ist seit Jahrzehnten die bekannteste Marke der Schweiz im Bereich hochwertiger Schlaflösungen. Wie prägt die... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,036 | 0,00 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| SPINEWAY | 0,117 | -0,85 % | Spineway: GMED approval for new production line dedicated to ESP prostheses - First production of LP-ESP intervertebral disc prostheses | Press release Ecully, July 3, 2025 - 6:30 p.m. SPINEWAY GMED approval for new production line dedicated to ESP prostheses First production of LP-ESP intervertebral disc prostheses Spineway... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,113 | -7,10 % | UniDoc Health Corp.: UniDoc Provides Update on Marketing Engagement | VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media... ► Artikel lesen | |
| VERU | 0,501 | -2,15 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| CLARIANE | 5,305 | -0,93 % | Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services network | Press release June 12th, 2025 Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services network Paris, June 12th, 2025 - Clariane (CLARI.PA... ► Artikel lesen | |
| SENSEONICS | 0,367 | -4,31 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results | Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately... ► Artikel lesen | |
| BONESUPPORT | 26,700 | +4,30 % | Bonesupport Holding AB: Upcoming CEO change. Emil Billbäck will transfer to a role as Senior Advisor. Torbjörn Sköld will start as CEO effective September 1st, 2025 | BONESUPPORT, a leading company in orthobiologics for the management of bone injuries, today announces the coming transition of leadership at Bonesupport.
Lennart Johansson states: Emil Billbäck will... ► Artikel lesen | |
| VIROMED MEDICAL | 4,100 | -3,76 % | EQS-Adhoc: Viromed Medical AG erwartet dynamisches Wachstum und veröffentlicht Prognose für 2025 und 2026 | EQS-Ad-hoc: Viromed Medical AG / Schlagwort(e): Prognose
Viromed Medical AG erwartet dynamisches Wachstum und veröffentlicht Prognose für 2025 und 2026
30.06.2025 / 15:36 CET/CEST
Veröffentlichung... ► Artikel lesen |
Das Unternehmen ACARIX AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,023 Euro und damit -18,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACARIX AB finden Sie auf Wallstreet Online.